{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-034162","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.938051+00:00","generated_at":"2026-05-15T08:58:56.343808+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ProMIS Neurosciences reports FY2025 net loss of $39.7M; Phase 1b fully enrolled, $75.5M financing closed","bullets":["Net loss of $39.7M in FY2025; R&D expense soared to $33.4M from $10.6M a year ago, driven by PRECISE-AD trial.","Cash of $6.1M at Dec 31, 2025; subsequent $75.5M private placement in Feb 2026 provides cash runway through 2027.","PRECISE-AD Phase 1b enrollment completed with 144 patients; six-month blinded interim data expected early Q3 2026.","PMN310 continues to show favorable safety profile with no treatment-related SAEs reported after over 12 months of dosing.","PMN310 granted FDA Fast Track Designation in July 2025; goal to advance directly into a single registrational study."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-034162","json":"https://secwatch.observer/filing/0001104659-26-034162.json","markdown":"https://secwatch.observer/filing/0001104659-26-034162.md","text":"https://secwatch.observer/filing/0001104659-26-034162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/0001104659-26-034162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/pmn-20260325x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:58:56.343808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71aa473be595233ee370744c2601ed4772b712dc","claim":"ProMIS Neurosciences Inc. reported the year ended December 31, 2025 results: net income $39.7 million.","evidence_excerpt":"For the year ended December 31, 2025, the Company reported a net loss of $39.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/0001104659-26-034162-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"$39.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}